Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM). Patients were included with recurrent primary GBM and progression within 6 months of ending standard treatment (radiotherapy and temozolomide). Bevacizumab and irinotecan were administered IV every 2 weeks. The first 10 patients received bevacizumab 5 mg/kg, but this was increased to 10 mg/kg after interim safety analysis. Irinotecan dose was based on whether patients were taking enzyme-inducing antiepileptic drugs or not: 340 and 125 mg/m(2), respectively. Cetuximab 400 mg/m(2) as loading dose followed by 250 mg/m(2) weekly was administered IV. Forty-three patients were enrolled in the trial, of which 32 were available for response. Radiographic responses were noted in 34%, of which 2 patients had complete responses and 9 patients had partial responses. The 6-month progression-free survival probability was 30% and median overall survival was 29 weeks (95% CI: 23-37 weeks). One patient had lacunar infarction, 1 patient had multiple pulmonary embolisms, and 3 patients had grade 3 skin toxicity, for which 1 patient needed plastic surgery. One patient was excluded due to suspicion of interstitial lung disease. Three patients had deep-vein thrombosis; all continued on study after adequate treatment. Cetuximab in combination with bevacizumab and irinotecan in recurrent GBM is well tolerated except for skin toxicity, with an encouraging response rate. However, the efficacy data do not seem to be superior compared with results with bevacizumab and irinotecan alone.
Hasselbalch
Benedikte
B
Department of Radiation Biology, The Finsen Center, Copenhagen University Hospital, Copenhagen, Denmark.
Lassen
Ulrik
U
Hansen
Steinbjørn
S
Holmberg
Mats
M
Sørensen
Morten
M
Kosteljanetz
Michael
M
Broholm
Helle
H
Stockhausen
Marie-Thérése
MT
Poulsen
Hans Skovgaard
HS
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000068818:Cetuximab; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007150:Immunohistochemistry; D000077146:Irinotecan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D016879:Salvage Therapy / Q000379:methods; D000077204:Temozolomide; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D003606:Dacarbazine; D000068818:Cetuximab; D002166:Camptothecin; D000077204:Temozolomide
Cancer Res. 1991 Apr 15;51(8):2164-72
2009534
Cancer Cell. 2005 Apr;7(4):301-11
15837620
J Clin Oncol. 1990 Jul;8(7):1277-80
2358840
Onkologie. 2006 Dec;29(12):563-7
17202826
J Clin Oncol. 2009 Feb 10;27(5):740-5
19114704
Cancer Res. 1997 Sep 15;57(18):4130-40
9307304
Int J Cancer. 2005 Dec 20;117(6):883-8
16152621
Neurosurgery. 2005;56(1):155-62; discussion 162
15617598
Eur J Cancer. 2008 Nov;44(16):2350-6
18789679
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
17317837
J Clin Oncol. 1999 Aug;17(8):2572-8
10561324
Cell. 2007 May 4;129(3):465-72
17482542
Neuro Oncol. 1999 Jan;1(1):44-51
11550301
J Clin Oncol. 2008 Dec 1;26(34):5610-7
18981465
Br J Cancer. 2007 Apr 10;96(7):1047-51
17353924
Cancer Res. 2003 Oct 15;63(20):6613-25
14583454
Cancer Biol Ther. 2006 Aug;5(8):912-4
16929166
Cancer. 2003 May 1;97(9 Suppl):2381-6
12712460
J Clin Oncol. 2010 Jun 10;28(17):2817-23
20458050
Acta Neuropathol. 2007 Mar;113(3):295-302
17235514
Cancer Res. 2004 Oct 1;64(19):6892-9
15466178
J Natl Cancer Inst. 2005 Jun 15;97(12):880-7
15956649
Ann Oncol. 2003 Apr;14(4):603-14
12649109
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
Cancer Res. 2006 Apr 15;66(8):3992-5
16618717
Anticancer Res. 2007 Sep-Oct;27(5A):3355-66
17970081
J Clin Oncol. 2004 Jan 1;22(1):133-42
14638850
Neuro Oncol. 2009 Feb;11(1):80-91
18784279
J Neurooncol. 2009 Apr;92(2):149-55
19043778
Oncogene. 2003 May 8;22(18):2812-22
12743604
J Clin Oncol. 2007 Oct 10;25(29):4557-61
17876013
Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94
18565358
Neuro Oncol. 2006 Apr;8(2):189-93
16533878
Eur J Cancer. 2009 May;45(7):1294-1303
19179066
Am J Pathol. 1997 Dec;151(6):1523-30
9403702
Clin Cancer Res. 1999 Feb;5(2):257-65
10037173
Neurosurgery. 2002 Oct;51(4):1005-13; discussion 1013-4
12234411
Acta Oncol. 2009;48(1):52-8
19031176
Clin Cancer Res. 2007 Mar 15;13(6):1663-74
17363519
Oncogene. 2005 Jun 23;24(27):4433-41
15806152
Clin Cancer Res. 1995 Nov;1(11):1311-8
9815926
J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56
11504770
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):873-82
17544000
N Engl J Med. 2005 Nov 10;353(19):2012-24
16282176
Clin Cancer Res. 2004 Oct 1;10(19):6522-7
15475439
Cancer Res. 2000 Mar 1;60(5):1383-7
10728703
Clin Cancer Res. 2000 Sep;6(9):3739-47
10999768
Br J Cancer. 2000 Sep;83(5):588-93
10944597
Clin Cancer Res. 2005 Nov 1;11(21):7841-50
16278407
J Neurooncol. 2003 May;62(3):297-303
12777082